期刊文献+

恶性胸腔积液管理进展

Progress of Management for Malignant Pleural Effusions
下载PDF
导出
摘要 恶性胸腔积液是由恶性肿瘤通过直接或间接侵犯胸膜或胸膜原发性肿瘤所致。它是癌症晚期常见的并发症,治疗难度大,预后较差。患者以MPE为首发症状或恶性肿瘤进展并发胸腔积液,往往提示病情已处于晚期,生存期仅4~7个月左右。目前,恶性胸腔积液治疗的方法较多,但是没有标准的治疗方法,总体疗效有限,由于其预后不佳,临床上多以姑息治疗手段为主。因此,采取积极有效的治疗措施以缓解患者症状、提高患者生存质量,显得尤为重要。文章综合性的回顾了恶性胸腔积液的治疗方法,就晚期恶性胸腔积液的管理进行简要分析。 Malignant pleural effusions(MPE)is one of the most common causes of pleural effusion.It is caused by direct or indirectly violation to the pleura or pleural primary tumor from malignant tumors.It is a common and difficult complication of advanced malignant diseases,with poor prognosis.Patients with MPE as the first symptom or malignant tumor progression complicated by pleural effusion often indicate that the disease is in the advanced stage,the survival period is only about 4~7 months.At present,there are a lot of therapies,but there is no standard treatment,the optimal treatment is controversial and the general effect is limited,because of its poor prognosis,several studies favor to local palliative approaches.Therefore,it is particularly important to take active and effective treatment measures to alleviate the symptoms of patients and improve the quality of life of patients.This article reviews the comprehensive treatment methods and current approaches to the management of malignant pleural effusion,and shows some advice to the future.
作者 杜小兵 刘双 DU Xiaobing;LIU Shuang(Department of Pulmonary and Critical Care Medicine,Peking University International Hospital,Beijing 102206,China)
出处 《中国继续医学教育》 2019年第16期88-91,共4页 China Continuing Medical Education
基金 “十二五”国家科技攻关计划(2012ZX09303016-001)
关键词 恶性胸腔积液 管理 进展 胸腔穿刺术 胸膜固定术 胸腔置管术 malignant pleural effusions management progress thoracocentesis pleurodesis indwelling pleural catheter
  • 相关文献

参考文献7

二级参考文献55

  • 1Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions[J]. Ann Intern Med,1994,120(1) :56-64.
  • 2Kuzniar TJ, Blum MG, Kasibowska-Kuzniar K, et al. Predictors of acute lung injury and severe hypoxemia in patients undergoing operative talc pleurodesis [J]. Ann Thorac Surg,2006,82(6) :1976-1981.
  • 3de Campos JR, Vargas FS, de Campos Werebe E, et al. Thoracoscopy talc poudrage: a 15-year experience[J]. Chest, 2001,119(3) :801-806.
  • 4Campos JR, Werebe EC, Vargas FS, et al. Respiratory failure due to insufflated talc[J]. Lancet, 1997,349(9047) : 251-252.
  • 5Maskell NA, Lee YC, Gleeson FV, et al. Randomized trials describing lung inflammation after pleurodesis with talc of varying particle size[J].Am J Respir Crit Care Med, 2004, 170(4) :377-382.
  • 6Janssen JP, Collier G, Astoul P, et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion:a prospective cohort study[J]. Lancet,2007,369(9572) :1535-1539.
  • 7Echavarria A, Pinz6n V, Bar6s JP, et al. Intracavitary treatment of malignant pleural effusion with iodine-povidone[J]. Rev Med Panama,1991,16(1) :69-74.
  • 8Agarwal R,Khan A,Aggarwal AN,et al. Efficacy & safety of iodopovidone pleurodesis: a systematic review & meta- analysis[J].ndian J Med Res,2012,135 : 297-304.
  • 9Olivares-Torres CA, Laniado-Laborin R, Chdvez-Garcia C, et al. Iodopovidone pleurodesis for recurrent pleural effusions [J]. Chest, 2002,122(2) :581-583.
  • 10Agarwal R, Aggarwal AN, Gupta D. Efficacy and safety of iodopovidone pleurodesis through tube thoracostomy [J]. Respirology, 2006,11 ( 1 ) : 105-108.

共引文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部